. 2021 Oct 18;3(1):R106–R120. doi: 10.1530/VB-21-0013
This work is licensed under a Table 1.
Summary of exercise interventions in rodents and humans investigating vascular function and health during and after chemotherapy exposure.
| Participants | Exercise intervention | Chemotherapy treatment | Vascular outcomes | Overall findings | |
|---|---|---|---|---|---|
| Rodent studies | |||||
| Matsuura et al. (34) | Sprague–Dawley rats: n = 40 per group |
Intervention group: Treadmill 5 days/week for 4 or 8 weeks, 30 min/day, 20–25 m/min, 15% gradient Sedentary group: No exercise |
Ex vivo exposure to 5-fluorouracil (7 × 10−5 to 7 × 10−3 M) | Endothelium-dependent vasodilation (aortic ring) | No diff intervention vs sedentary group at 4 weeks ↑ EDV intervention group only at 8 weeks |
| eNOS protein content | No diff intervention vs sedentary group at 4 weeks ↑ eNOS content intervention group only at 8 weeks |
||||
| Betof et al. (35) | Sprague–Dawley rats: n = 10 per group |
Intervention group: Treadmill 5 days/week, for 6 weeks, 30 min/day, 50–60% max velocity Sedentary group: No exercise |
Intraperitoneal doxorubicin injection (1 mg/kg/day, 10 days) | Vasodilation response to acetylcholine | Impaired in both groups No diff intervention vs sedentary group |
| eNOS content and activity | No diff intervention vs sedentary group | ||||
| Scott et al. (36) | BALB/c female mice: n = 11 per group |
Intervention group: voluntary wheel running for 18 days Sedentary group: No wheel |
Intraperitoneal cyclophosphamide injection (100 mg/kg on days 7, 9, and 11) | Microvessel density | ↑ Microvessel density intervention vs sedentary group |
| Human studies | |||||
| Jones et al. (11) | Stage IIB–IIIC breast cancer, age 51± 6 years, BMI 29 ± 5 kg/m2, n = 10 per group |
Intervention:12 weeks, three sessions/week cycling at 60–100% for 30–45 min Control: usual care only |
Four cycles of neoadjuvant doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2) every 3 weeks | baFMD | No diff pre- to post-chemotherapy treatment No diff intervention vs sedentary group |
| Lee et al. (12) | Stage I–III breast cancer, age 49 ± 8 years, BMI 33 ± 8 kg m2, n = 15 per group |
Intervention: 8 weeks, three sessions/week 20-min cycling HIIT (7×1-min at 90% PPO) Control: usual care only |
(neo)Adjuvant doxorubicin and cyclophosphamide administered every 2 weeks for four cycles (dosage details not available) | baFMD cIMT pre- to post- treatment |
↓ baFMD pre- to post-chemotherapy treatment sedentary group ↑ baFMD pre- to post-chemotherapy treatment intervention group ↑ cIMT pre- to post-chemotherapy treatment sedentary group No change cIMT pre- to post-chemotherapy treatment intervention group |
| Mijwel et al. (13) | Stage I–IIIa breast cancer, age 51 ± 13 years, BMI 25 kg/m2 (n = 23) |
Resistance training: 12 weeks, two sessions/week 2–3 sets of 8–12 reps 70–80% 1-RM, 3×3-min of HIIT cycling (n = 6) Aerobic training: 12 weeks, two sessions/week, 20 min cycling/running RPE 13–15, 3×3-min of HIIT cycling (n = 7) Control: usual care only (n = 10) |
Anthracyclines, taxanes, or a combination of the two (dosage details not provided) | Capillaries per fibre pre to post-treatment: | ↓ Capillaries pre- to post-chemotherapy treatment sedentary group ↑ Capillaries pre- to post-chemotherapy treatment aerobic intervention group ↑ Capillaries pre- to post-chemotherapy treatment resistance intervention group |
baFMD, brachial flow-mediated dilation; cIMT, carotid intima media thickness; EDV, endothelium-dependent vasodilation; PPO, peak power output; RPE, rating of perceived exertion.